CNS Clinical Trials in Russia

Apr 7, 2014

In Russia, most CNS clinical studies have been conducted in MS, epilepsy, AD, stroke, depression and schizophrenia. A number of leading Russian biopharmaceutical companies and life science institutional investors are engaged in the development of new disease-modifying therapies in these ...

Read More

New Standards in Alzheimer’s Disease Trial Design

Apr 7, 2014

Over the last decade, the only new treatment for Alzheimer’s to make it to market is memantine (Namenda™).  The number of failed drug programs in that span provides a roadmap of scientific approaches that initially appear promising, but flame out ...

Read More